CoChat

What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review

Open access
Castro Santos, Henrique, Gama Marques, João · 2021 · Porto Biomedical Journal

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.

Abstract

Background: Psilocybin is a predominant agonist of 5HT 1A and 5HT 2A/C receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedelic renaissance. Methods: In this paper we performed a systematic review of the clinical trials conducted so far regarding the therapeutic effects of psilocybin on psychiatric disorders. The eligibility criteria included clinical trials that assessed psilocybin's potential therapeutic effects on patients with psychiatric disorders. Nine hundred seven articles were found and screened in regard to the title, from which 94 were screened through abstract and 9 met the eligibility criteria and were included. Results: The papers published focused on 3 disorders: depression, obsessive-compulsive disorder (OCD) and substance use disorder (namely tobacco and alcohol). Psilocybin has shown a relatively safe profile and very promising results, with reductions found on most of the psychiatric rating scales’ scores. Research on depression showed the most solid evidence, supported by 3 randomized controlled trials. Studies on OCD and substance use disorder showed more limitations due to their open-label design. Conclusions: Altogether, the results from the studies reviewed in this paper suggest a substantial therapeutic potential. This calls for further research to confirm the results observed so far and further explain the underlying mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/j.pbj.0000000000000128

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow of citations according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta).
Figure 1 Flow of citations according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. Johnson, 2014, Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction, J Psychopharmacol (Oxford, England) [Internet]., 28, 0269881114548296-

Cited by

See all 40

Metadata

Authors
Castro Santos, H., & Gama Marques, J.
Affiliations
Hospital Júlio de Matos, Centro Hospitalar Psiquiátrico de Lisboa
Venue
Porto Biomedical Journal
Published
2021-01
Volume
6
Issue
1
Pages
e128
ISSN
2444-8664 (ISSN-L)
OpenAlex
W3133450788
Cited by
37
References
68
Citations by year
2026: 3 · 2025: 8 · 2024: 10 · 2023: 10 · 2022: 3 · 2021: 3
FWCI
0.86
Type
journal article
Language
en
Open access
Locations
  • Porto Biomedical Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psilocybin, psychedelic therapy, mental illness, depression, obsessive-compulsive disorder, substance use disorders, tobacco use, alcohol consumption, treatment efficacy, safety profile

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. https://app.cochat.ai/papers/10.1097/j.pbj.0000000000000128
The paper
Castro Santos, H., & Gama Marques, J. (2021). What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomedical Journal. https://doi.org/10.1097/j.pbj.0000000000000128

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.